KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Non-Current Deferred Tax Liability (2016 - 2017)

Travere Therapeutics (TVTX) has disclosed Non-Current Deferred Tax Liability for 5 consecutive years, with $1.2 million as the latest value for Q2 2017.

  • For the quarter ending Q2 2017, Non-Current Deferred Tax Liability fell 90.2% year-over-year to $1.2 million, compared with a TTM value of $1.2 million through Jun 2017, down 90.2%, and an annual FY2016 reading of $6.4 million, down 73.59% over the prior year.
  • Non-Current Deferred Tax Liability was $1.2 million for Q2 2017 at Travere Therapeutics, down from $4.4 million in the prior quarter.
  • Across five years, Non-Current Deferred Tax Liability topped out at $39.9 million in Q1 2015 and bottomed at $141000.0 in Q4 2014.
  • Average Non-Current Deferred Tax Liability over 5 years is $10.9 million, with a median of $7.4 million recorded in 2016.
  • The sharpest move saw Non-Current Deferred Tax Liability tumbled 94.58% in 2014, then surged 17153.9% in 2015.
  • Year by year, Non-Current Deferred Tax Liability stood at $2.6 million in 2013, then crashed by 94.58% to $141000.0 in 2014, then soared by 17153.9% to $24.3 million in 2015, then tumbled by 73.59% to $6.4 million in 2016, then plummeted by 81.54% to $1.2 million in 2017.
  • Business Quant data shows Non-Current Deferred Tax Liability for TVTX at $1.2 million in Q2 2017, $4.4 million in Q1 2017, and $6.4 million in Q4 2016.